SP
BIO icon

Symmetry Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Symmetry Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-484
Closed -$232K – 583
2023
Q1 		$232K Sell
484
-169
-26% -$79.1K 0.01% 507
2022
Q4 		$275K Sell
653
-243
-27% -$98.1K 0.02% 478
2022
Q3 		$374K Sell
896
-219
-20% -$109K 0.03% 381
2022
Q2 		$552K Hold
1,115
– – 0.04% 291
2022
Q1 		$628K Hold
1,115
– – 0.04% 308
2021
Q4 		$842K Hold
1,115
– – 0.05% 251
2021
Q3 		$807K Hold
1,115
– – 0.05% 272
2021
Q2 		$718K Sell
1,115
-131
-11% -$79.7K 0.05% 309
2021
Q1 		$712K Sell
1,246
-4
-0.3% -$2.37K 0.05% 287
2020
Q4 		$729K Buy
1,250
+1
+0.1% +$570 0.06% 259
2020
Q3 		$644K Buy
1,249
+323
+35% +$164K 0.05% 254
2020
Q2 		$418K Buy
926
+133
+17% +$58.7K 0.05% 183
2020
Q1 		$278K Buy
793
+219
+38% +$80.5K 0.06% 223
2019
Q4 		$212K Buy
+574
New +$202K 0.04% 313
2019
Q3 		– Sell
-644
Closed -$201K – 339
2019
Q2 		$201K Hold
644
– – 0.04% 316
2019
Q1 		$197K Hold
644
– – 0.03% 309
2018
Q4 		$150K Buy
+644
New +$173K 0.04% 296

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Symmetry Partners's BIO Position: Q2 2023 in Review

Symmetry Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 484 shares — an estimated $232K sold.

Symmetry Partners first reported a position in BIO in Q4 2018 and held it in 17 quarters. The position peaked at $842K in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Symmetry Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Symmetry Partners sold 484 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $232K.
  • Symmetry Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 17 quarters.
  • Symmetry Partners's Bio-Rad Laboratories Class A position peaked at $842K in Q4 2021.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Symmetry Partners's 13F filing for Q2 2023, filed 5 Jul 2023.